Literature DB >> 26705848

Dopamine System Dysregulation and the Pathophysiology of Schizophrenia: Insights From the Methylazoxymethanol Acetate Model.

Anthony A Grace1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26705848      PMCID： PMC4870144          DOI： 10.1016/j.biopsych.2015.11.007

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  10 in total

1.  A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.

Authors:  Kathryn M Gill; Daniel J Lodge; James M Cook; Shamim Aras; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2011-05-11       Impact factor: 7.853

2.  Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model.

Authors:  Kathryn M Gill; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2014-04-30       Impact factor: 5.176

Review 3.  Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia.

Authors:  Anthony A Grace
Journal:  Neuropharmacology       Date:  2011-05-23       Impact factor: 5.250

Review 4.  Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies.

Authors:  M Laruelle; A Abi-Dargham
Journal:  J Psychopharmacol       Date:  1999-12       Impact factor: 4.153

5.  Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2011-02-18       Impact factor: 5.176

6.  A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.

Authors:  Holly Moore; J David Jentsch; Mehdi Ghajarnia; Mark A Geyer; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2006-04-11       Impact factor: 13.382

7.  Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.

Authors:  Kathryn M Gill; James M Cook; Michael M Poe; Anthony A Grace
Journal:  Schizophr Bull       Date:  2014-01-24       Impact factor: 9.306

8.  Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.

Authors:  Yijuan Du; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

9.  A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Margarita M Behrens; Anthony A Grace
Journal:  J Neurosci       Date:  2009-02-25       Impact factor: 6.167

10.  Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis.

Authors:  Paul Allen; Christopher A Chaddock; Oliver D Howes; Alice Egerton; Marc L Seal; Paolo Fusar-Poli; Isabel Valli; Fern Day; Philip K McGuire
Journal:  Schizophr Bull       Date:  2011-05-02       Impact factor: 9.306
  10 in total
  19 in total

Review 1.  Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.

Authors:  Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 2.  Potential Roles of Redox Dysregulation in the Development of Schizophrenia.

Authors:  Diana O Perkins; Clark D Jeffries; Kim Q Do
Journal:  Biol Psychiatry       Date:  2020-04-02       Impact factor: 13.382

3.  Correlation Between Levels of Delusional Beliefs and Perfusion of the Hippocampus and an Associated Network in a Non-Help-Seeking Population.

Authors:  Rick P F Wolthusen; Garth Coombs; Emily A Boeke; Stefan Ehrlich; Stephanie N DeCross; Shahin Nasr; Daphne J Holt
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-07-13

Review 4.  Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.

Authors:  Roger Hudson; Walter Rushlow; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

5.  Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.

Authors:  Daniel Paul Eisenberg; Lisa Yankowitz; Angela M Ianni; Dani Y Rubinstein; Philip D Kohn; Catherine E Hegarty; Michael D Gregory; José A Apud; Karen F Berman
Journal:  Neuropsychopharmacology       Date:  2017-04-07       Impact factor: 7.853

6.  Female rats are resistant to the long-lasting neurobehavioral changes induced by adolescent stress exposure.

Authors:  Katharina Klinger; Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Eur Neuropsychopharmacol       Date:  2019-07-29       Impact factor: 4.600

Review 7.  The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention.

Authors:  Anthony A Grace; Felipe V Gomes
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

Review 8.  Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.

Authors:  Anthony A Grace
Journal:  Nat Rev Neurosci       Date:  2016-06-03       Impact factor: 34.870

9.  30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed Into the Developmental Risk Factor Model of Psychosis.

Authors:  Robin M Murray; Vishal Bhavsar; Giada Tripoli; Oliver Howes
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

Review 10.  The origin of NMDA receptor hypofunction in schizophrenia.

Authors:  Kazu Nakazawa; Kiran Sapkota
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.